Present mortality in Parkinson's disease: the ratio of observed to expected deaths with a method to calculate expected deaths
Excess mortality,i.e. more deaths than expected in a similar normal population, has been reduced in Parkinson's disease by levodopa. A California series and a large collaborative study throughout the United States show the ratio of observed to expected deaths to be normal. In contrast, a New York study with similar patients and a Montreal group of much more severely disabled patients show greater mortality. The reasons for these differences are unclear, but some variation in results may be attributed to different methods of calculating expected deaths to derive the ratio of observed to expected deaths.
Unable to display preview. Download preview PDF.
- Barbeau, A.: Six years of high-level levodopa therapy in severely akinetic parkinsonian patients. Arch. Neurol.33, 333–338 (1976).Google Scholar
- Cotzias, G. C., Papavasiliou, P. S., Gellene, R.: Modification of parkinsonism—chronic treatment with L-dopa. N. Eng. J. Med.280, 337–345 (1969).Google Scholar
- Diamond, S. G., Markham, C. H., Treciokas, L. J.: Long term experience with levodopa: efficacy, progression and mortality. Proc. Vth Int. Symp. Parkinson's Disease, Vienna 1975 (in press).Google Scholar
- Hoehn, M. M., Yahr, M. D.: Parkinsonism: onset, progression and mortality. Neurology17, 427–442 (1967).Google Scholar
- Kurland, L. T.: Epidemiology: incidence, geographic distribution and genetic considerations. In: Pathogenesis and Treatment of Parkinsonism (Field, W. S., ed.). Springfield, Ill.: Charles C Thomas. 1958.Google Scholar
- Markham, C. H., Treciokas, L. J., Diamond, S. G.: Parkinson's disease and and levodopa—a five year follow up and review. West. J. Med.121, 188–206 (1974).Google Scholar
- Sweet, R. D., McDowell, F. H.: Five years' treatment of Parkinson's disease with levodopa. Ann. Int. Med.83, 456–463 (1975).Google Scholar
- U.S. Public Health Service: United States life tables. U.S. Department of Health, Education and Welfare, Washington, D.C., Vol. 1, No. 1, 1959 to 1960.Google Scholar
- Yahr, M. D., Duvoisin, R. C., Hoehn, M. M., Schear, M. J., Barrett, R. E.: L-dopa (L-3,4-dihydroxyphenylalanine)—its clinical effects in parkinsonism. Trans. Am. Neurol. Assoc.93, 56–63 (1968).Google Scholar